Specific genetic variants were found to play a role in the response to anti-VEGF treatment for age-related macular degeneration in a real-life retrospective study conducted in six Spanish tertiary care hospitals.
The study included 403 eyes of 403 consecutive patients treated with Lucentis (ranibizumab, Genentech) for AMD. In all cases, a loading dose of three monthly injections was administered, followed by as-needed treatment. Over 12 months of follow-up, patients were classified as good or poor responders based on visual acuity gain of at least five letters, central foveal thickness, and
Uncategorized